Novo Nordisk has been firmly thrust into the limelight given the kerfuffle that has accompanied the stellar showing of semaglutide for obesity, but much of the Danish drugmaker’s focus is to seek out innovation in the diabetes space that has been its bread and butter.
Novo Nordisk Still On The Lookout For Diabetes Innovations
The Denmark-based major intends to build on its heritage in diabetes and is keen to hear from innovators in a space where prevalence is on the rise but is not being served by improved new products.
